A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
To evaluate the efficacy and safety of SHR-A1811 with or without pertuzumab versus trastuzumab, pertuzumab and docetaxel in HER2-Positive Recurrent or Metastatic Breast Cancer
HER2-PositiveRecurrent or Metastatic Breast Cancer
DRUG: SHR-A1811 Injection|DRUG: SHR-A1811 Injection ； Pertuzumab Injection|DRUG: Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection
Progression Free Survival by Blinded Independent Central Review, from first dose to disease progression, or death, whichever comes first, up to 3 years
Progression Free Survival by investigators, from first dose to disease progression, or death, whichever comes first, up to 3 years|Overall Survival, from first dose to death, up to 6 years|Objective Response Rate, from first dose to disease progression or death, whichever comes first, up to 3 years|Duration of response, from first dose to disease progression or death, whichever comes first, up to 3 years|AE, from Day1 to 40 or 90 days after last dose|Incidence and severity of serious adverse events (SAE), from Day1 to 40 or 90 days after last dose
To evaluate the efficacy and safety of SHR-A1811 with or without pertuzumab versus trastuzumab, pertuzumab and docetaxel in HER2-Positive Recurrent or Metastatic Breast Cancer